Risk Stratification Of Clinical Stage I (Csi) Non-Seminomatous Germ Cell Testicular Tumors (Nsgct): A Retrospective Analysis Of Experience At Indiana University (Iu).

e16052Risk Stratification of Clinical Stage I (CSI) Non-Seminomatous Germ Cell Testicular Tumors (NSGCT): A Retrospective Analysis of Experience at Indiana University (IU) Background: Nearly 50% of testicular germ cell tumors are NSGCT. For those with CSI disease, standard treatment options include active surveillance, retroperitoneal lymph node dissection (RPLND), or adjuvant chemotherapy. The cure rate is 99% regardless of which approach is chosen. However, there exists a need for better risk stratification of CSI into low and high risk of recurrence. We aim to evaluate the risk factors for relapse in CSI patients on surveillance, comparing histopathological risk factors of embryonal carcinoma predominance (EC) and lymphovascular invasion (LVI). Methods: This study is a retrospective analysis of all pts with CSI NSGCT seen at diagnosis at IU from January 2000- 2015. Results: We identified 424 consecutive pts of which 170 (40%) had surveillance. 50 (29%) had recurrence on surveillance. 76% relapsed in pe...